CoChat

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Open access

The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.

Abstract

The significant and growing global prevalence of diabetes continues to challenge people with diabetes (PwD), healthcare providers, and payers. While maintaining near-normal glucose levels has been shown to prevent or delay the progression of the long-term complications of diabetes, a significant proportion of PwD are not attaining their glycemic goals. During the past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials and real-world studies have shown that the use of AID systems is safe and effective in helping PwD achieve their long-term glycemic goals while reducing hypoglycemia risk. Thus, AID systems have recently become an integral part of diabetes management. However, recommendations for using AID systems in clinical settings have been lacking. Such guided recommendations are critical for AID success and acceptance. All clinicians working with PwD need to become familiar with the available systems in order to eliminate disparities in diabetes quality of care. This report provides much-needed guidance for clinicians who are interested in utilizing AIDs and presents a comprehensive listing of the evidence payers should consider when determining eligibility criteria for AID insurance coverage.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/endrev/bnac022

Cites

144 of 144 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract
Graphical abstract CC BY-NC-ND · PubMed Central
Figure 1. Automated Insulin Delivery Report: Page 1. Upper Panel, 1, The upper left section contains the clinically important time in ranges (bar) and internationally recognized goals to allow the clinician to quickly ascertain the overall level of glucose management. 2, The essential device use information, including percentage of time AID and CGM were active, along with infusion set and sensor change information, is at the top of the first page to alert the clinician of any data sufficiency or safety concerns. 3, The middle upper panel contains essential glucose metrics, including average glucose, glucose management indicator (GMI), and glucose variability calculated as percentage coefficient of variation. 4, The final component of the upper panel is a table containing detailed insulin metrics divided by how the insulin is delivered, either automatically by the AID system (called automated insulin) or user-initiated insulin delivery. Automated insulin metrics include the average amount of insulin delivered per day and the calculated average units per hour. In addition, the daily average automated correction bolus delivered along with the calculated percentage of total daily dose (TDD) is listed. Detailed insulin metrics describing the average user-initiated amounts of bolus insulin given for food, correction insulin given with the food bolus, and correction only insulin are listed. In addition, the average amount of user overrides insulin delivered per day and average overrides per day are listed. Middle Panel, Below the AGP are the AID system settings, including the insulin to carbohydrate (ICR) (1 unit insulin/g CHO), correction factor (CF) (or ISF, Insulin Sensitivity Factor) (1 unit insulin/mg/dL or 1 unit insulin/mmol/L), algorithm glucose set point and active insulin time (that may or may not be adjusted depending on the AID system). Lower Panel, The mealtime glucose metrics begin 1 hour before the meal to show the user’s average glucose level prior to the meal and ends 4 hours after the start of the meal. The start of the meal is the time when the user-initiated bolus is delivered. The number of days with meal boluses recorded is listed to help identify mealtimes where user-initiated bolus insulin may have been omitted. The average amount of carbs per mealtime is also listed. Of note, automated correction boluses may have also been delivered (in AID systems that have this feature) during the post-meal period and may be reflected in the late post-meal period.
Figure 1. Automated Insulin Delivery Report: Page 1. Upper Panel, 1, The upper left section contains the clinically important time in ranges (bar) and internationally recognized goals to allow the clinician to quickly ascertain the overall level of glucose management. 2, The essential device use information, including percentage of time AID and CGM were active, along with infusion set and sensor change information, is at the top of the first page to alert the clinician of any data sufficiency or safety concerns. 3, The middle upper panel contains essential glucose metrics, including average glucose, glucose management indicator (GMI), and glucose variability calculated as percentage coefficient of variation. 4, The final component of the upper panel is a table containing detailed insulin metrics divided by how the insulin is delivered, either automatically by the AID system (called automated insulin) or user-initiated insulin delivery. Automated insulin metrics include the average amount of insulin delivered per day and the calculated average units per hour. In addition, the daily average automated correction bolus delivered along with the calculated percentage of total daily dose (TDD) is listed. Detailed insulin metrics describing the average user-initiated amounts of bolus insulin given for food, correction insulin given with the food bolus, and correction only insulin are listed. In addition, the average amount of user overrides insulin delivered per day and average overrides per day are listed. Middle Panel, Below the AGP are the AID system settings, including the insulin to carbohydrate (ICR) (1 unit insulin/g CHO), correction factor (CF) (or ISF, Insulin Sensitivity Factor) (1 unit insulin/mg/dL or 1 unit insulin/mmol/L), algorithm glucose set point and active insulin time (that may or may not be adjusted depending on the AID system). Lower Panel, The mealtime glucose metrics begin 1 hour before the meal to show the user’s average glucose level prior to the meal and ends 4 hours after the start of the meal. The start of the meal is the time when the user-initiated bolus is delivered. The number of days with meal boluses recorded is listed to help identify mealtimes where user-initiated bolus insulin may have been omitted. The average amount of carbs per mealtime is also listed. Of note, automated correction boluses may have also been delivered (in AID systems that have this feature) during the post-meal period and may be reflected in the late post-meal period.CC BY-NC-ND · PubMed Central
Figure 2. Automated Insulin Delivery Report: Page 2. 1, The top part of the daily profile displays the CGM tracing and is color coded to match the time in ranges bar (eg, green when in target range of 70 to 180 mg/dL, red when less than 70 mg/dL ang gold when above 180 mg/dL). The user-entered carbohydrate is shown above the CGM tracing in gray circles and total amount of carbohydrates is shown on the bar right. Just below the glucose tracing is the amount of user-initiated bolus insulin in dark purple with the common “insulin sail” to show that active bolus insulin is available. 2, The lower section of the daily profile contains the automated basal insulin tracing in light purple with the left y-axis showing the rate in units/hour and the automated correction boluses delivered with the right y-axis showing units per hour. The total amount of correction boluses delivered in each 1-hour period of the day is shown by the thin blue line with the number of corrections in that hour shown in parenthesis below the total insulin amount. Total insulin amount for each day is shown on the right of each daily profile using icons to designate how the insulin was delivered along with the TDD.
Figure 2. Automated Insulin Delivery Report: Page 2. 1, The top part of the daily profile displays the CGM tracing and is color coded to match the time in ranges bar (eg, green when in target range of 70 to 180 mg/dL, red when less than 70 mg/dL ang gold when above 180 mg/dL). The user-entered carbohydrate is shown above the CGM tracing in gray circles and total amount of carbohydrates is shown on the bar right. Just below the glucose tracing is the amount of user-initiated bolus insulin in dark purple with the common “insulin sail” to show that active bolus insulin is available. 2, The lower section of the daily profile contains the automated basal insulin tracing in light purple with the left y-axis showing the rate in units/hour and the automated correction boluses delivered with the right y-axis showing units per hour. The total amount of correction boluses delivered in each 1-hour period of the day is shown by the thin blue line with the number of corrections in that hour shown in parenthesis below the total insulin amount. Total insulin amount for each day is shown on the right of each daily profile using icons to designate how the insulin was delivered along with the TDD.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 1

  1. University of Cambridge

Cited by

See all 443

Metadata

Authors
Phillip, M., Nimri, R., Bergenstal, R. M., Barnard-Kelly, K., Danne, T., Hovorka, R., Kovatchev, B. P., Messer, L. H., Parkin, C. G., Ambler-Osborn, L., Amiel, S. A., Bally, L., Beck, R. W., Biester, S., Biester, T., Blanchette, J. E., Bosi, E., Boughton, C. K., Breton, M. D., Brown, S. A., Buckingham, B. A., Cai, A., Carlson, A. L., Castle, J. R., Choudhary, P., Close, K. L., Cobelli, C., Criego, A. B., Davis, E., de Beaufort, C., de Bock, M. I., DeSalvo, D. J., DeVries, J. H., Dovc, K., Doyle, F. J., Ekhlaspour, L., Shvalb, N. F., Forlenza, G. P., Gallen, G., Garg, S. K., Gershenoff, D. C., Gonder-Frederick, L. A., Haidar, A., Hartnell, S., Heinemann, L., Heller, S., Hirsch, I. B., Hood, K. K., Isaacs, D., Klonoff, D. C., Kordonouri, O., Kowalski, A., Laffel, L., Lawton, J., Lal, R. A., Leelarathna, L., Maahs, D. M., Murphy, H. R., Nørgaard, K., O’Neal, D., Oser, S., Oser, T., Renard, E., Riddell, M. C., Rodbard, D., Russell, S. J., Schatz, D. A., Shah, V. N., Sherr, J. L., Simonson, G. D., Wadwa, R. P., Ward, C., Weinzimer, S. A., Wilmot, E. G., & Battelino, T.
Affiliations
  • Tel Aviv University (IL)
  • HealthPartners (US)
  • Southern Health NHS Foundation Trust (GB)
  • Kinderkrankenhaus auf der Bult (DE)
  • University of Cambridge (GB)
  • University of Virginia (US)
  • University of Colorado Anschutz (US)
  • CGParkin Communications, Inc. , Henderson, NV , USA
  • Joslin Diabetes Center (US)
  • King's College London (GB)
  • University of Bern (CH)
  • Jaeb Center for Health Research (US)
  • University of Utah (US)
  • Vita-Salute San Raffaele University (IT)
  • Stanford Medicine (US)
  • Close Concerns (United States) (US)
  • Oregon Health & Science University (US)
  • University of Leicester (GB)
  • University of Padua (IT)
  • The Kids Research Institute Australia (AU)
  • Diabetes & Endocrine Care Clinique Pédiatrique DECCP/Centre Hospitalier Luxembourg, and Faculty of Sciences, Technology and Medicine, University of Luxembourg, Esch sur Alzette, GD Luxembourg/Department of Paediatrics, UZ-VUB , Brussels , Belgium
  • Department of Paediatrics, University of Otago , Christchurch , New Zealand
  • Baylor College of Medicine (US)
  • Amsterdam University Medical Centers (NL)
  • Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, UMC - University Children’s Hospital, Ljubljana, Slovenia, and Faculty of Medicine, University of Ljubljana , Ljubljana , Slovenia
  • Harvard University (US)
  • Lucile Packard Children's Hospital (US)
  • The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children’s Medical Center of Israel , 49202 Petah Tikva , Israel
  • McGill University (CA)
  • Cambridge University Hospitals NHS Foundation Trust (GB)
  • Science Consulting in Diabetes GmbH , Kaarst , Germany
  • University of Sheffield (GB)
  • University of Washington (US)
  • Cleveland Clinic (US)
  • Diabetes Research Institute, Mills-Peninsula Medical Center , San Mateo, CA 94010 , USA
  • Breakthrough T1D (US)
  • University of Edinburgh (GB)
  • University of Manchester (GB)
  • University of East Anglia (GB)
  • University of Copenhagen (DK)
  • Department of Medicine and Department of Endocrinology, St Vincent’s Hospital Melbourne, University of Melbourne , Melbourne , Australia
  • Department of Endocrinology, Diabetes, Nutrition, Montpellier University Hospital, and Institute of Functional Genomics, University of Montpellier, CNRS, INSERM , Montpellier , France
  • York University (CA)
  • Biomedical Informatics Consultants LLC , Potomac, MD , USA
  • University of Florida (US)
  • Yale University (US)
  • University of Nottingham (GB)
  • University of Ljubljana (SI)
Corresponding author
  • Phillip, Moshe
  • Nimri, Revital
Venue
Endocrine Reviews
Published
2022-09-06
Volume
44
Issue
2
Pages
254-280
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W4294783598
Cited by
443
References
144
Citations by year
2026: 102 · 2025: 121 · 2024: 141 · 2023: 76 · 2022: 3
FWCI
63.20
Type
journal article
Language
en
Open access
Locations
  • Endocrine Reviews (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Repository@Nottingham (University of Nottingham) (publishedVersion, cc-by-nc-nd)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc-nd)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Pure Amsterdam UMC (acceptedVersion, cc-by)
  • HAL (submittedVersion, cc-by-nc-nd)
  • Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by-nc-nd)
  • Digital Commons-TMC (Texas Medical Center) (submittedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by-nc-nd)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion, cc-by-nc-nd)
  • Figshare (submittedVersion, cc-by-nc-nd)
  • Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, cc-by)
  • Open Access CRIS of the University of Bern
Funders
  • Amgen
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Leona M. and Harry B. Helmsley Charitable Trust
  • University of Virginia
  • Bigfoot Biomedical
  • Insulet Corporation
  • MannKind Corporation
  • Dexcom
  • Steno Diabetes Center Copenhagen (SDCC 3.E Technology)
  • Cardinal Health
  • Tandem Diabetes Care
  • National Institute for Health and Care Research (16/35/01, CL-2020-14-801)
  • Novo Nordisk
  • Roche Diabetes Care
  • National Institutes of Health (UL1TR001863)
  • University of Colorado Denver
  • Abbott Diabetes Care
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK121942, K23DK122017, R01DK129553, P30DK045735)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
artificial pancreas, diabetes management, glycemic control, hypoglycemia risk, insulin pump therapy, continuous glucose monitoring, eligibility criteria, clinical guidelines
MeSH terms
Blood Glucose, Diabetes Mellitus, Type 1, Humans, Hypoglycemic Agents, Insulin, Blood Glucose Self-Monitoring, Consensus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.